Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: de la cruz f. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Maerevoet M, Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Van Den Neste E, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M. Maerevoet M, et al. Among authors: de la cruz f. J Hematol Oncol. 2021 Jul 16;14(1):111. doi: 10.1186/s13045-021-01122-1. J Hematol Oncol. 2021. PMID: 34271963 Free PMC article. Clinical Trial.
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Schuster M, Zijlstra J, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Follows G, Egyed M, Offner F, Vassilakopoulos T, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M, Maerevoet M. Schuster M, et al. Among authors: de la cruz f. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):483-494. doi: 10.1016/j.clml.2021.12.016. Epub 2021 Dec 25. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35078739 Clinical Trial.
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes-Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group. Pardal E, et al. Among authors: de la cruz f. Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 May 6. Am J Hematol. 2018. PMID: 29658143 Free article.
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Gutierrez A, Bento L, Diaz-Lopez A, Barranco G, Garcia-Recio M, Lopez-Guillermo A, Dlouhy I, Rovira J, Rodriguez M, Sanchez Pina JM, Baile M, Martín A, Novelli S, Sancho JM, García O, Salar A, Bastos-Oreiro M, Rodriguez-Salazar MJ, Fernandez R, de la Cruz F, Queizan JA, González de Villambrosia S, Cordoba R, López A, Luzardo H, García D, Sastre-Serra J, Garcia JF, Montalban C, Cabanillas F, Rodríguez J. Gutierrez A, et al. Among authors: de la cruz f. Eur J Haematol. 2020 May;104(5):400-408. doi: 10.1111/ejh.13364. Epub 2020 Feb 18. Eur J Haematol. 2020. PMID: 31804029 Free PMC article.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Garcia-Sanz R, et al. Among authors: de la cruz f. Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009. Ann Oncol. 2019. PMID: 30657848 Free article. Clinical Trial.
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.
Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M. Alcoceba M, et al. Among authors: de la cruz f. Blood. 2013 Aug 22;122(8):1448-54. doi: 10.1182/blood-2013-02-483420. Epub 2013 Jul 10. Blood. 2013. PMID: 23843497 Free article.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Giné E, de la Cruz F, Jiménez Ubieto A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Giné E, et al. Among authors: de la fuente a, de la cruz f. J Clin Oncol. 2022 Apr 10;40(11):1196-1205. doi: 10.1200/JCO.21.02321. Epub 2022 Jan 14. J Clin Oncol. 2022. PMID: 35030036 Free PMC article. Clinical Trial.
Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years.
Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, Gonzalez-Medina J, Revilla N, Sampol A, Domingo-Domenech E, de la Cruz F, Morales A, Rodriguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Martínez C, et al. Among authors: de oteyza jp, de la cruz f. Ann Hematol. 2017 Jan;96(1):9-16. doi: 10.1007/s00277-016-2832-6. Epub 2016 Oct 18. Ann Hematol. 2017. PMID: 27752822
468 results